Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation of Narcolepsy

Inclusion Criteria:

• Patients must be ≥ 18 years old.

• Patients must be scheduled for an MSLT for a potential diagnosis of hypersomnia (ArmA only).

• Patients are able/willing to consent and willing to undergo the nocturnal PSG, MSLT,and Dreem 3S monitoring described in the protocol.

• (for Known NT1 arm [Arm B] only) Deemed safe to discontinue prohibited medicationsas per protocol.

• (for Known NT1 arm [Arm B] only) Agree to discontinue driving and operating heavymachinery while untreated for their condition and according to the PI's judgement.

Exclusion Criteria:

• Patients under 18 years old.

• If a patient is taking a wake promoting drug and is unsafe to temporarily reduce ordiscontinue the drug during the 2 weeks prior to nocturnal PSG and MSLT due to theiroccupation, need to drive or operate heavy machinery, role as a primary caretaker,medical risk of temporarily discontinuing from drug therapy, or any other reason atthe discretion of the subject's treating physician or study physicians/PIs.

• Patients suffering from mental and/or physical disorders that could interfere withthe study protocol or the interpretation of the results (exclusion based on clinicaljudgment).

• Shift workers or patients working unusual hours will be excluded. 5. Patients with ahistory of stroke or epilepsy.

• Patients with an implanted hypoglossal nerve stimulator or a diagnosis of moderateto severe sleep apnea (Apnea-Hypopnea Index (AHI) 3% >15) not adherent on positiveairway pressure therapy (usage 30-day window prior to enrollment date reveals <70%days use at least hours; patients treated with non-PAP treatments will not beeligible).

• Patients who are unable to sign an informed consent form, or unable to have a legalguardian who is able to sign along with the patient's assent.

• Patients who are deemed ineligible by the site PI or treating physician for anyother reason.